Mycosis Fungoides / Sézary Syndrome · Mogamulizumab monotherapy (1.0 mg/kg IV weekly × 5, then q2 weeks)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`REG-MOGAMULIZUMAB`

ID	`IND-MF-ADVANCED-1L-MOGA`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-MF-SEZARY`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB. Standard-of-care for advanced MF / Sézary where mogamulizumab accessible. Ukraine access major barrier.

Used By

Algorithms

ALGO-MF-SEZARY-1L - ALGO-MF-SEZARY-1L
ALGO-MF-SEZARY-2L - ALGO-MF-SEZARY-2L